Beating the Odds: The Improbable Story of How Perseverance, Belief, and Luck Led to the Approval of the First Life-Changing Immune Therapy for Type 1 Diabetes

Read Next

• ATTD Brings Together Top Minds in Diabetes Research

  Leading researchers gathered for the ATTD meeting, which featured more than 50 studies presented by JDRF-funded researchers.

  Read More about ATTD Brings Together Top Minds in Diabetes Research

• Top Researchers Gather for the 17th ATTD Conference

  This year's Advanced Technologies & Treatments for Diabetes (ATTD) meeting, which will be held on March 6-9, will have 50 JDRF-funded presenters.

  Read More about Top Researchers Gather for the 17th ATTD Conference

• JDRF T1D Fund Invests in vTv Therapeutics

  With an investment from the JDRF T1D Fund, vTv Therapeutics will run a phase III clinical trial of cadisegliatin (TTP399), an adjunct therapy to insulin.

  Read More about JDRF T1D Fund Invests in vTv Therapeutics